Clinical trials: Rectum Carcinoma
Neoplasms, Colorectal Neoplasms
Study of PRoliferation and Apoptosis in Rectal Cancer, Predictive & Prognostic biOmarkers: Histopathology and Imaging
This study tests biopsy and tissue from patients who have been treated for primary rectal cancer at the Royal Marsden Hospital between 2011 and 2013, who have an mrTRG score at post-chemoradiotherapy MRI.
- Conditions
- Neoplasms, Colorectal Neoplasms, Rectal Diseases, Gastrointestinal Neoplasms
- Trial name
- SOPRANO (NCT02486094)
- Where
- United Kingdom
- Volunteers
- 148 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Localized Malignant Solid Neoplasm, Anal Cancer
Distance-Based Exercise to Preserve Function and Prevent Disability
This clinical trial studies whether an exercise program can be successfully delivered to patients receiving treatment for cancer through virtual sessions and allow patients to exercise in their own home.
- Conditions
- Localized Malignant Solid Neoplasm, Anal Cancer, Bladder (Urothelial, Transitional Cell) Cancer, Breast Cancer
- Trial name
- DEFEND (NCT07059884)
- Testing
- Exercise intervention, Telemedicine, Aerobic Exercise Intervention
- Where
- 23 sites in United States
- Volunteers
- 104 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Colon Cancer, Colon Polyp
Comparison of Two Preparations for the Study of the Colon Through Colonoscopy
Compare the quality of bowel preparation between two groups of patients, who will undergo two different preparations: 1. Moviprep + diet; 2. Plenvu + diet
- Conditions
- Colon Cancer, Colon Polyp, Colon Adenoma, Colon Rectal Cancer
- Trial name
- NCT04497935
- Testing
- PLENVU, MoviPrep
- Where
- Portugal
- Volunteers
- 613 people, healthy volunteers welcome
- Sponsor
- Unidade Local de Saúde do Alto Ave, EPE
Rectal Cancer
A Study of PEP503(Radio-enhancer) With Radiotherapy and Chemotherapy for Patients With Rectal Cancer
This phase Ib/II study is a prospective, open-label, single arm, nonrandomized study of PEP503(radio-enhancer). There are 2 portions in this study.
- Trial name
- NCT02465593
- Testing
- PEP503, 5-fluorouracil, capecitabine
- Where
- Taiwan
- Volunteers
- 32 people
- Sponsor
- PharmaEngine
Breast Cancer, Colo-rectal Cancer
Feasibility Study of a Molecular Karyotype Using a Very High-throughput Sequencing Approach, the "Massive Parallel Sequencing" on Circulating Tumor DNA
There are several types of circulating DNA: DNA from patient's existing cells, foetal DNA in the case of pregnant woman, and tumoral DNA in the case of patients with cancer.
- Trial name
- NCT04104633
- Testing
- Blood samples
- Where
- France
- Volunteers
- 18 people
- Sponsor
- Centre Hospitalier Henri Duffaut - Avignon
Rectal Cancer
Cetuximab, 5-FU and Radiation as Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer
The standard treatment for rectal cancer is to receive the chemotherapeutic drug 5-fluorouracil (5-FU) with radiation therapy before having surgery to remove the rectal cancer. This is known as neoadjuvant chemoradiotherapy.
- Trial name
- NCT00611858
- Testing
- Cetuximab, 5-Fluorouracil, Radiation
- Where
- 4 sites in United States
- Volunteers
- 13 people
- Sponsor
- Dana-Farber Cancer Institute
Low Rectal Cancer
Nodes-sparing Short-course Radiation Combined With CAPOX and Tislelizumab for MSS Middle and Low Rectal Cancer
This is an open-label, prospective, multicenter phase II clinical trial to evaluate modified short-course radiation (Radiation targeting the tumor bed without irradiating surrounding tumor-draining lymph nodes) combined with…
- Trial name
- mRCAT (NCT05972655)
- Testing
- Modified short-course radiotherapy, PD-1 antibody, Capecitabine
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Sir Run Run Shaw Hospital
Colon Rectal Cancer Duke Stage Stageval
A Trial of Pre-Operative Chemoradiotherapy Using Capecitabine, Radiation & Cetuximab, in Rectal Cancer
A Pilot Trial of Pre-Operative Chemoradiotherapy Using Capecitabine (Xelodaâ), External Beam Radiation and Cetuximab (Erbitux®) Followed by Definitive Surgery in Patients With Localized (Non-Metastatic) Rectal Cancer
- Trial name
- NCT01310985
- Testing
- Capecitabine (Xelodaâ), XRT & Cetuximab (Erbitux®)
- Where
- Saudi Arabia
- Volunteers
- 15 people
- Sponsor
- King Faisal Specialist Hospital & Research Center
Colo-rectal Cancer, Colon Cancer
Delayed Colorectal Cancer Care During Coronavirus Disease (COVID-19) Pandemic (DECOR-19)
To understand and analyse the global impact of COVID-19 on outpatient services, inpatient care, elective surgery, and perioperative colorectal cancer care, a DElayed COloRectal cancer surgery (DECOR-19) survey was conducted in…
- Conditions
- Colo-rectal Cancer, Colon Cancer, Rectal Cancer, Oncology
- Trial name
- DECOR-19 (NCT04488549)
- Testing
- Survey
- Where
- Italy
- Volunteers
- 1,051 people
- Sponsor
- Treviso Regional Hospital
Rectal Cancer
A Prospective Phase II Study of Individualized Neoadjuvant Chemoradiotherapy for Rectal Cancer Based on Recurrence Risk
A Prospective Phase II Study of Individualized Neoadjuvant Chemoradiotherapy for Rectal Cancer Based on Recurrence Risk
- Trial name
- NCT04664504
- Testing
- Concurrent Chemoradiotherapy Radiotherapy, Short-course Radiotherapy, Local dose increase of Short-course Radiotherapy
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Jing Jin, M.D.
Rectal Cancer
Multicenter Study on Preservation Versus Excision of Denonvilliers Fascia in L-PANP Surgery
TME (Total mesorectum excision) is the golden standard of radical resection for mid-low rectal cancer. However, the damage of pelvic autonomic nerve following with TME principle will lead to high incidence of urinary and sexual…
- Trial name
- NCT02435758
- Testing
- Preservation of Denonvilliers Fascia during L-PANP surgery
- Where
- China
- Volunteers
- 262 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Cancer
Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer
RATIONALE: Learning about the relationship between platinum levels in the blood and neurotoxicity in patients receiving oxaliplatin may help plan treatment and may help patients live more comfortably.
- Trial name
- NCT00274885
- Testing
- oxaliplatin, management of therapy complications
- Where
- 6 sites in France
- Volunteers
- 58 people
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Stage II Rectal Cancer, Stage III Rectal Cancer
Quicksilver II Pilot Study
This pilot study is being done to answer the following question: Will patients with margin-clear Stage 2 or 3 rectal cancer who don't require a colostomy agree to be randomized to 'surgery only' or 'chemotherapy and then…
- Trial name
- NCT07688135
- Testing
- Direct-to-surgery (i.e., no neoadjuvant chemotherapy), Control Group
- Volunteers
- 18 people
- Sponsor
- Mount Sinai Hospital, Canada
Rectal Cancer
Hydralazine as a Demethylating Agent in Rectal Cancer
Clinically feasible dose of Hydralazine for ~ 3 months, by virtue of its demethylating effect, will: 1. Result in re-expression of epigenetically silenced TSGs in rectal cancer specimens. 2.
- Trial name
- NCT00575640
- Testing
- Hydralazine
- Sponsor
- University of Arkansas
Rectal Cancer
Evaluate Efficacy, Morbidity and Functional Outcome of Endoscopic TranAnal Proctectomy vs Standard Transabdominal Laparoscopic Proctectomy for Rectal Cancer
Standard surgical treatment of mid and low rectal cancer is total mesorectal excision (TME). Originally performed by open surgery, TME demonstrated improved local control and reduced urogenital morbidity.
- Trial name
- ETAP (NCT02584985)
- Testing
- ETAP, Standard Transabdominal Laparoscopic Proctectomy
- Where
- France
- Volunteers
- 226 people
- Sponsor
- Institut Paoli-Calmettes
Colorectal Cancer
Cetuximab and Capecitabine in Treating Patients With Metastatic Colorectal Cancer That Failed Irinotecan Treatment
RATIONALE: Monoclonal antibodies such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00538291
- Testing
- cetuximab, capecitabine, gene expression analysis
- Where
- 2 sites in United States
- Volunteers
- 13 people
- Sponsor
- City of Hope Medical Center
Colorectal Cancer
PET and CT Scans in Patients With Locally Advanced Primary Rectal Cancer That Can Be Removed During Surgery
RATIONALE: Diagnostic procedures, such as PET and CT scans, may improve the ability to detect the extent of locally advanced primary rectal cancer and may also help to measure a patient's response to treatment.
- Trial name
- NCT00004891
- Testing
- chemotherapy, computed tomography, conventional surgery
- Where
- United States
- Volunteers
- 149 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Locally Advanced Rectal Cancer
Assess the Efficacy of Radiotherapy and Sequential Chemotherapy and AK104 Before TME Surgery for Local CRC（AK104-IIT-13）
This study is a single-arm, open-label, multicenter clinical study to evaluate the efficacy and safety of preoperative short-course radiotherapy combined with AK104 and chemotherapy + TME surgery in patients with advanced rectal…
- Trial name
- AK104-IIT-13 (NCT05794750)
- Testing
- AK104 injection, TME surgery, Capecitabine
- Volunteers
- 50 people
- Sponsor
- JIN JING
Bowel Cancer, Polyp Rectal
Use of a Novel Camera to Check the Bowel After Polyp or Tumour Removal
1.1 Polyps or tumours in the lower part of the bowel (rectum) can be removed using instruments inserted through the bottom which avoids major surgery and the possibility of a stoma bag (colostomy).
- Conditions
- Bowel Cancer, Polyp Rectal, Rectal Cancer, Rectal Adenocarcinoma
- Trial name
- R-ALERT (NCT07341126)
- Testing
- LumenEye X1 digital rectoscope
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- University of Edinburgh
KRAS-mutant Non-small Cell Lung Cancer (NSCLC), KRAS-mutant Pancreatic Ductal Adenocarcinoma (PDAC)
A Phase 1 Dose Escalation and Dose Expansion Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
The main purpose of the trial is to assess whether the trial drug, KST-6051, is safe and tolerable when administered orally, alone or in combination with other anticancer agents, to adults with advanced or metastatic solid tumors…
- Conditions
- KRAS-mutant Non-small Cell Lung Cancer (NSCLC), KRAS-mutant Pancreatic Ductal Adenocarcinoma (PDAC), KRAS-mutant Colorectal Cancer (CRC), Other KRAS-mutant Solid Tumors
- Trial name
- NCT07458347
- Testing
- KST-6051, Gemcitabine/nab-paclitaxel, Cetuximab
- Where
- 9 sites in United States
- Volunteers
- 545 people
- Sponsor
- Kestrel Therapeutics, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.